Promoter holding
64.27%
KP
Kesar Pharma Limited - Due diligence report
A 360° intelligence report on Kesar Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals -…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Kesar Pharma — 360° Intelligence Report
Generated from MCA filings & public records83/100
Trust Score
Low Risk
Kesar Pharma is assessed as Low Risk with a Trust Score of 83/100. Kesar Pharma is an active public limited indian non-government company incorporated in 2011, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 26 Jul 2026 from the latest processed filings. Kesar Pharma Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
83/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
75/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
35/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
55/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 35/100 Caution Indicated
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Elevated gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 6 open (10.58 cr) · 5 satisfied (14.65 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 6 | 48.0 cr |
| Hdb Financial Services Limited | 1 | 48.0 cr |
| Sidbi | 4 | 48.0 cr |
Compliance Score: 75/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- 1 auditor resignation(s) filed - latest: Nilesh Desai & Co. on 2020-02-04.
- Delayed payments to MSME suppliers disclosed (300 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| PARTH HEMANT PARIKH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KEVIN ATUL VASANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PRAKASH AMBALAL PATEL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KALPESH NAVNITLAL SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Rumit Bharatbhai Gopani | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 5 directors on the board.
- No disqualified or deactivated DINs.
- 2 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
1
Group entities
1
Capital events
4 allotment(s) · 1 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Kesar Finechem Private Limited | Subsidiary Company | 74.00% |
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 55 · Distress 90
Growth signals & trust indicators
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
Operating for 14+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
6 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 4.13 cr.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence82/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment57/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 6 open charge(s) of 10.58 cr already registered.
- Compliance record supports lending.
Investor view69/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
07 May 2025
Director ceased
KEVIN ATUL VASANI
Director ceased
Rumit Bharatbhai Gopani
15 Apr 2025
Director appointed
KEVIN ATUL VASANI (Director)
Director appointed
Rumit Bharatbhai Gopani (Director)
31 Mar 2025
Latest balance sheet
Filed with ROC
19 Feb 2025
Charge satisfied
Others
31 Jan 2025
Charge created
Hdb Financial Services Limited - 6.06 cr
05 Feb 2024
Charge created
Sidbi - 1.40 cr
28 Mar 2023
Charge created
Sidbi - 62.76 Lakh
11 Nov 2022
Charge satisfied
Sidbi
23 Jun 2021
Charge created
Sidbi - 1.40 cr
22 Feb 2021
Director ceased
PARTH HEMANT PARIKH
06 Feb 2021
Charge created
Others - 55.00 Lakh
29 Jan 2021
Director ceased
BRIJESH RAJENDRAKUMAR PATEL
10
Key Observations
Auto-generated from the data aboveRevenue declined 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
5 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 4 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Orchid Bio-Tech Limited | U24231DL2005PLC133511 | Delhi, Delhi, India |
| Radha Kishan Bishan Dass Rang Rasayan Private Limited | U74120UP2012PTC050987 | Hathras, Uttar Pradesh, India |
| Memphis Vision Care Private Limited | U52100GJ2014PTC079356 | Chhatral, Gujarat, India |
| Sellwell Pharmaceuticals Limited | U24232MP1989PLC005424 | Na, Madhya Pradesh, India |
| Unim Pharmalab Ltd | U24231GJ1994PLC022962 | Himatnagar, Gujarat, India |
| R P L (India) Pharmaceuticals Private Limited | U24239DL2002PTC115402 | New Delhi, Delhi, India |
| Setu | U24304MH2020PTC337274 | Mumbai, Maharashtra, India |
| Ja Sterile Private Limited | U74999GJ2018PTC101210 | Visnagar, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Kesar Pharma before audits and certifications: compliance score 75/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Kesar Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 35/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 55/100, margin trends, ownership structure and peer set for Kesar Pharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 83/100, distress signals and MSME payment-delay disclosures - know whether Kesar Pharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Kesar Pharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Kesar Pharma an active company?
Kesar Pharma has MCA status “Active” with a compliance score of 75/100 (Low Risk).
Is Kesar Pharma financially healthy?
Kesar Pharma has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.
Should I do business with Kesar Pharma?
Its overall Trust Score is 83/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Kesar Pharma?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 5 active director(s) are on record.
Does Kesar Pharma have loans or charges against its assets?
6 open charge(s) are registered against its assets, and 5 earlier charge(s) stand satisfied.
Is Kesar Pharma up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 75/100 (Low Risk).
Is it risky to lend to Kesar Pharma?
Its Credit Risk Score is 35/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
